Sustained impact of subcutaneous immunotherapy among patients with allergic rhinitis who experienced treatment delay due to the COVID‐19 pandemic: A multicenter, two‐arm, real‐world study.

Keywords: COVID-19; delayed therapy; depression; efficacy; subcutaneous immunotherapy (SCIT) EN COVID-19 delayed therapy depression efficacy subcutaneous immunotherapy (SCIT) 1 3 3 03/30/22 20220301 NES 220301 To the editor, Subcutaneous immunotherapy (SCIT) is highly effective for seasonal pollinosis and perennial disease in patients with mite allergy.1 SCIT usually involves administering a gradually increasing dose of the specific allergens to allergic patients until the effective dose is reached then followed by administering the maintenance doses for 3 years or more.2 As the end of 2019 witnessed an outbreak of coronavirus disease 2019 (COVID-19) in China, clinical, educational, research, and community responsibilities have been tremendously influenced in the whole world. Sustained impact of subcutaneous immunotherapy among patients with allergic rhinitis who experienced treatment delay due to the COVID-19 pandemic: A multicenter, two-arm, real-world study The time for 83.6% of SCIT delayed patients was less than 10 weeks, 10-20 weeks for 14.5% patients, and only 1.9% patients were more than 20 weeks (Figure 1A). [Extracted from the article]